Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS: Trastuzumab Combined With Oral Chemotherapy or Endocrine Therapy in Stage I Breast Cancer
NCT04383275Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- May 2020
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease-Free Survival at 5 years. Started May 2020; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04383275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383275.